News
LUCD
1.050
-1.87%
-0.020
Weekly Report: what happened at LUCD last week (0622-0626)?
Weekly Report · 2d ago
Lucid Diagnostics Shareholders Approve Stock Authorization Increase
TipRanks · 06/24 21:32
Lucid Diagnostics shareholders approve charter amendment raising authorized common shares to 400 million
PUBT · 06/24 21:01
Globus Medical (GMED) Surges 5.1%: Is This an Indication of Further Gains?
NASDAQ · 06/22 10:38
Weekly Report: what happened at LUCD last week (0615-0619)?
Weekly Report · 06/22 09:35
Weekly Report: what happened at LUCD last week (0608-0612)?
Weekly Report · 06/15 09:36
Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case
Benzinga · 06/08 15:25
Lucid Diagnostics Is Maintained at Buy by Ascendiant Capital
Dow Jones · 06/08 10:14
Weekly Report: what happened at LUCD last week (0601-0605)?
Weekly Report · 06/08 09:34
Weekly Report: what happened at LUCD last week (0525-0529)?
Weekly Report · 06/01 09:36
Weekly Report: what happened at LUCD last week (0518-0522)?
Weekly Report · 05/25 09:37
Major Insider Move at Lucid Diagnostics Signals Growing Confidence
TipRanks · 05/22 02:04
Lucid Diagnostics director Dennis Matheis acquires 245,000 common shares for $245,270.00
PUBT · 05/21 20:20
Weekly Report: what happened at LUCD last week (0511-0515)?
Weekly Report · 05/18 09:37
Lucid Diagnostics Is Maintained at Buy by Maxim Group
Dow Jones · 05/15 20:05
Lucid Diagnostics Price Target Cut to $2.00/Share From $3.00 by Maxim Group
Dow Jones · 05/15 20:05
Maxim Group Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2
Benzinga · 05/15 19:55
Lucid Diagnostics price target lowered to $2 from $3 at Maxim
TipRanks · 05/15 15:26
PAVmed Q1 FY26 net loss widens to $7 million; operating expenses rise to $8.1 million
PUBT · 05/15 12:03
Lucid Diagnostics Price Target Maintained With a $2.50/Share by BTIG
Dow Jones · 05/15 11:47
More
Webull provides a variety of real-time LUCD stock news. You can receive the latest news about Lucid Diagnostics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LUCD
Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company's products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The Company is a subsidiary of PAVmed Inc.